Company ProfilePremium

Cann Global Limited

Company Profile Analysis

Ticker: CGB.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Cann Global Limited - Company showcase

Year Founded & Workforce

2007

Cann Global Limited logo

Cann Global Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Cann Global Limited Overview

Cann Global Limited is a Sydney-based micro-cap that turned a dormant bauxite explorer (Queensland Bauxite) into a diversified hemp, plant-based food, cosmeceutical and medicinal cannabis group between 2016 and 2019. At its peak it had a hemp-seed and chia health-food wholesale business (T12 Holdings / Organic Markets Direct, sold into Costco Australia and exported to Vietnam), a 55%-owned Thai hemp cultivation and extraction services venture, a 50:50 medicinal-tablet JV with Canada's Canntab Therapeutics, a 50:50 skincare JV with Israel's Pharmocann (later the Fuss Pot brand), and Technion-linked multiple sclerosis research. It never reached scale. Revenue peaked at A$1.78m in FY2020 and fell to A$0.56m in FY2022. Cumulative losses reached A$50.7m, funded by repeated, highly dilutive equity raisings. A prolonged voluntary suspension from September 2022 tied to an unconsummated Thailand acquisition, unpaid ASX fees and unlodged FY2023 accounts led to removal from the ASX in March 2024. It now survives only as a registered unlisted shell-like entity.


Company's own description (FY2021/FY2022 filings, paraphrased). Cann Global described itself as a medicinal cannabis and natural food and beauty products business operating in the health and wellness industry. It stressed partnerships with specialists in Australia, the USA, Israel, Asia and Canada, and said it worked within relevant legislation to give practitioners, patients and consumers access to safe, effective and sustainable products [4E-FY21]. The FY2022 financial statements describe the group as a for-profit entity engaged mainly in the legal growing and cultivation of hemp and medicinal cannabis products and in mineral exploration in Australia [4E-FY22].

Operating divisions as presented to investors (FY2020–FY2022):

  1. Food (Health Foods) — hemp seed and chia products (seed, oil, protein, flour, capsules, by-products, smoothie blends) through T12 Holdings / Organic Markets Direct and the Vitahemp, EM Super Foods, Australian Grown Naturals, Black Bag and later Grass Roots brands. This was the only consistent revenue generator.

  2. Hemp Cultivation & Processing — hemp hulling in Australia (Hemp Hulling Co (QLD) Pty Ltd, 55%) and broad-acre CBD hemp services in Asia through Cann Global Thailand (55%) and Cann Global Asia (55%).

  3. Skincare / Cosmeceutical — premium hemp-seed-oil skincare first developed in the 50:50 Pharmocann JV, later sold under the wholly owned Fuss Pot brand after the JV was dissolved in July 2022.

  4. Medicine — the Canntab Therapeutics Australia JV (50:50), which imported pharmaceutical-grade CBD hard tablets (later branded Instacann, using SMEDDS technology) via the TGA Special Access Scheme B and Authorised Prescriber pathways, plus MS-focused cannabis research with Technion (Israel) and NICM.

  5. Mining — the residual South Johnstone bauxite project, Queensland (EPM 18463, later referenced as MDL 2004), carried at A$2.28m.

Revenue model. Revenue was almost entirely product sales (goods transferred at a point in time). In FY2022, goods made up A$537.5k of A$562.3k (95.6%); services were A$7.6k and management/rent recharges A$17.3k [4E-FY22]. There was no subscription or licensing revenue. Thai cultivation services (FY2020 services revenue A$151.2k) and a Thai "plant-funding" investor model (FY2022 liability A$254.8k) were the only service-type streams.

Value-chain position. The company's main role was mid-stream wholesale and branding of commodity health foods, buying seed and sub-contracting farmers rather than growing at scale. In FY2021 it suspended its own hemp-seed cultivation and seed-bank breeding programme in favour of contract farming [4E-FY21]. In medicinal cannabis it was a downstream importer/distributor of a partner's product, not a licensed manufacturer.

Customer types and end-markets. Retail (Costco Australia; direct-to-consumer web stores), wholesale/white-label distributors, export distributors (Epco Food Co, Vietnam), equine feed (white label), Thai licensed cultivators (AA Bio Co Ltd, Green Pharma Botanical), a US seed buyer (Naga Organics LLC), and prescribing doctors/pharmacies via the TGA access schemes.

Independent characterisation. Cann Global was a sub-scale holding company with many small, loosely connected ventures across three continents and no defensible core asset. Its corporate overhead (A$3.5–4.2m a year in the corporate segment, FY2020–FY2022) was 2–7 times group revenue. The business depended on related-party service arrangements (Australian Gemstone Mining Pty Ltd, controlled by the founder) and on frequent, deeply discounted equity issues. It was effectively a cash shell with a modest food distribution business attached by FY2022. At 30 June 2022, cash of A$9.24m was about 97% of net assets [4E-FY22].

Strategy

Stated strategy themes (paraphrased from FY2020–FY2022 releases):

FY2020: Grow food division sales with an export focus (China, Southeast Asia); bring Canntab tablets and other medical cannabis products into Australia; expand Asian operations; move towards profitability through operational efficiency [4E-FY20].

FY2021: Refocus on direct-to-consumer channels in Australia and abroad; rationalise the product and brand portfolio towards higher-margin lines; launch premium hemp skincare in Australia and Europe; launch Canntab tablets; prepare an MS clinical trial with NICM; keep little or no debt [4E-FY21].

HY2022: The CEO cited three new revenue streams launched and "four growth pillars" focused on differentiation [HY22].

FY2023: Pivot to acquisition-led transformation: assess several "value-based" acquisition proposals, then exclusive due diligence on Thai cannabis assets intended to sell into Thailand and later Europe and Australia; brand streamlining and cost cuts to preserve cash [ASX-ANN].

Initiatives announced in the last 24 months (October 2024 – October 2026). None publicly announced. The company has been unlisted since March 2024 and has issued no public updates since then. The only public records in the window are ASIC registry actions (strike-off initiated January 2026, reversed February 2026) [DL].

ESG commitments. None disclosed.

Medium-term financial targets / guidance. Never provided.

Products & Services

Pricing models were not publicly disclosed for any product line. Launch years are taken from ASX releases where available.

Food division (Cannabis segment)

Product / brandDescription & specificationsTarget customerLaunch / latest yearFlagship offerings & notesSource
VitaHemp hemp seed oil capsulesOrganic premium hemp seed oil daily capsuleRetail (Costco), consumersCostco first order Aug 2019 (6,900 bottles)Flagship Costco SKU[BNA], [4E-FY20]
Organic Hemp Protein powderHemp protein powderCostco and retailAdded to Costco range FY2020FY2022 revenue A$94.2k[4E-FY20], [4E-FY22]
Hulled hemp seed (hearts)Food-grade hulled hemp seed; raw seed sourced from contract farmers (e.g., Midlands Tasmania supply agreement)Wholesale, export (Vietnam), retailFY2020 peak (A$1.59m seed sales)Largest single line in FY2020[4E-FY20], [4E-FY21]
Hemp seed oilCulinary/nutritional oilRetail/wholesaleOngoingFY2021 A$291.8k; FY2022 A$108.9k[4E-FY21], [4E-FY22]
Hemp flourMilled flourRetail/wholesaleOngoingFY2022 A$10.1k[4E-FY22]
Hemp by-productsProcessing by-productsWholesale/feedOngoingFY2021 A$57.2k[4E-FY21]
Smoothie blendsHemp-based blendsRetailDiscontinued by FY2022FY2021 A$1.7k[4E-FY21]
Chia seedWholesale chia (Organic Markets Direct)Wholesale, Vietnam exportOngoingFY2021 A$381.6k; FY2022 A$105.7k[4E-FY21], [4E-FY22]
Chia oil soft-gel capsulesPlant-based omega-3 capsule; company claimed the highest omega-3 content of any plant-based product on the marketCostco, white-label distributorDeveloped FY2020, Costco order FY2021Also white-labelled[4E-FY20], [4E-FY21]
Chia/hemp equine feedHorse feed productWhite-label customerFY2021White label only[4E-FY21]
Hemp pet food rangePet foodRetailDevelopment FY2020Commercial outcome not disclosed[4E-FY20]
Grass RootsPlant-based, nutritionist-endorsed health-food range for everyday meals and snacks; replaced older brand portfolio after FY2021 rationalisationRetail/DTC consumersc. FY2022Core consumer food brand by 2022[SWS], profile data
EM Super Foods, Australian Grown Naturals (AGN), Black BagLegacy T12 health-food brands (superfoods, Australian-grown lines)Retail/wholesaleAcquired Jul 2019Rationalised from FY2022[4E-FY20]
Organic Markets Direct (OMD)Health-food wholesaler: hemp seed products, chia, Green Leaf Stevia, cacao and similarRetailers, wholesalersAcquired Jul 2019Channel business[4E-FY20]

Hemp cultivation & processing

OfferingDescriptionCustomerYearNotesSource
Hemp hulling (Hemp Hulling Co, Coolum Beach QLD)Food-grade hemp seed dehullingInternal supply and third parties55% from Jul 2019Voluntary administration Mar 2022[4E-FY20], [4E-FY22]
Thai cultivation & extraction services (CGT)Full-service hemp cultivation/extraction under licences held by Thai partners (AA Bio Co Ltd, Green Pharma Botanical)Thai licence holdersFrom Jun 2020First-period profit A$143.3k[4E-FY20], [4E-FY21]
Auto-flowering feminised CBD hemp seedSeed genetics for outdoor off-season cultivation in Asia; 5m seeds ordered by Naga Organics LLC (USA), valued at US$750kGrowers/seed buyersFY2020Delivery of the full order not disclosed[4E-FY20]
Plant-funding programme (Thailand)Investors fund cultivation per plant and receive a fixed fee per plant after harvest/extractionInvestors (first UK investor in FY2022)FY2021A$203.5k received FY2022; recorded as a liability[4E-FY21], [4E-FY22]
Seed bank & plant genetics (MCL)Cannabis/hemp genetics, including the "Tabulum Project" triploid trialsInternal R&DAcquired with MCLFully written down by FY2021[ASX-ANN], [4E-FY21]

Skincare (Cosmeceutical)

OfferingDescriptionCustomerYearNotesSource
Fuss PotHemp-powered premium skincare: an oil, a serum and a cream with hemp seed oil as the main active and Australian native botanicals; organic certification pursuedConsumers (DTC web, Australia), EU B2BSoft launch Paris CBD Expo Oct 2021 and Canberra Nov 2021; CBD-based range shown in Italy May 2022Moved to 100% ownership after Pharmocann JV dissolved Jul 2022[4E-FY21], [4E-FY22], [SWS]

Medicine

OfferingDescriptionCustomerYearNotesSource
Canntab CBD tablets (12.5 mg, 25 mg)Pharmaceutical-grade, uniform-dose hard cannabinoid tablets made in CanadaPatients via TGA SAS-B and Authorised Prescriber schemes; prescribers/pharmaciesFirst shipment cleared Aug 2021Distributed with MedCan's "Cann I help" prescribing service until MedCan terminated Jul 2022[4E-FY21], [4E-FY22]
InstacannBrand combining natural cannabis extracts with a self-micro-emulsifying drug delivery system (SMEDDS) tabletPrescribers/patientsc. 2022Positioned as an alternative to oilsProfile data (MarketScreener)
MS cannabis chemovar (Technion / NICM)Strain identified by Dr Dedi Meiri's Technion lab as stopping, and in some cases reversing, MS progression in vitro and in vivo; draft human trial protocol written by NICM Health Research InstituteFuture pharmaceuticalResults Jun 2020; protocol 2021Commercial rights held via the Pharmocann JV; no human trial start disclosed[ASX-ANN], [4E-FY21]
Olivia's Choice formulaMedical cannabis formulation IP licensed from director John EasterlingPatientsAgreement Dec 2019Not launched; raw materials could not be imported under Australian law[4E-FY20], [4E-FY21]

Mining

AssetDescriptionStatusSource
South Johnstone Bauxite Project, QueenslandBauxite exploration tenement EPM 18463 (renewed to 25 May 2022 after part relinquishment). FY2022 notes refer to MDL 2004, renewed to 31 Oct 2022Carrying value A$2.278m at 30 Jun 2022. Current tenure status not publicly disclosed[4E-FY21], [4E-FY22]

Financial Narrative

Margins and growth

Revenue CAGR FY2019–FY2022 is +5.4% a year (A$480.6k to A$562.3k over three years). This hides a spike-and-collapse: revenue rose +270.7% in FY2020 with the T12 acquisition, then fell −16.5% in FY2021 (COVID impact on Vietnam export partner Epco and less Thai service income) and −62.2% in FY2022 (deliberate portfolio rationalisation, loss of export sales, Hemp Hulling Co administration). FY2019 revenue growth is shown as 0 because FY2018 trading revenue is not available in the sources reviewed.

Expense composition

Impairments by year:

  • FY2019: A$2,902.9k fair-value loss on financial assets plus A$485.0k receivables impairment plus A$13.7k exploration written off.

  • FY2021: A$308.6k exploration, A$242.7k receivables, A$200.0k Koegas investment and A$138.0k seed bank.

  • FY2022: A$2,691.3k goodwill, A$1,880.9k loss on HHC disposal, A$270.1k JV investments and A$31.4k receivables.

Balance sheet

Notes:

  • The FY2020 going-concern note refers to "net current liabilities of $2,042,216". The balance sheet itself shows positive working capital of the same amount (current assets A$8,770.8k less current liabilities A$6,728.6k). This is a wording error in the filing.

  • At 30 June 2018 (opening FY2019 balances), cash was A$6,409.3k and total equity A$11,549.4k [4E-FY20].

Cash flow

FY2021 capex = PP&E A$7.2k + intangibles A$37.9k + exploration A$136.0k. FY2022 capex = PP&E A$27.2k + intangibles A$69.1k + capital works A$11.3k. Investment in equity-accounted JVs (A$390.6k in FY2021; A$461.1k in FY2022) is excluded from capex.

Commentary on trends, inflections and drivers

Revenue. The single inflection was the T12 acquisition, effective 1 July 2019. T12 alone contributed A$1.60m of FY2020 revenue [4E-FY20]. After FY2020 the food business shrank on three fronts:

  • Export sales to Vietnam collapsed when Epco was disrupted by COVID-19.

  • Management rationalised the product range in Q4 FY2021, accepting lower revenue for higher margins.

  • In FY2022 the group lost Hemp Hulling Co to administration and exited low-margin lines.

Revenue at A$0.56m in FY2022 was only 17% above FY2019, before any acquisitions.

Gross margin. Gross margin peaked at 26.4% in FY2020 and turned negative (−13.9%) in FY2022. Seed and related product cost (A$573.6k) exceeded total sales (A$562.3k), which points to inventory clearance or write-downs at below cost [4E-FY22].

Operating losses. Operating losses were driven by overhead, not product economics. In FY2022, administrative and corporate expenses (A$2.25m), directors' fees (A$0.41m) and share-based payments (A$0.42m) together were 5.5 times revenue. FY2020 losses were inflated by A$2.13m of research spending (Technion MS programme) and A$2.01m of finance costs on high-cost convertibles (L1 Capital, Obsidian) and seed-capital loans carrying 20% conversion discounts or premiums.

Balance sheet. Converting about A$3.73m of convertibles and loans to equity in FY2021, plus A$6.65m of new equity, made the balance sheet effectively debt-free. Cash peaked at A$10.57m in June 2021. The FY2022 write-off of all A$4.32m of goodwill (MCL, T12, HHC) left the company with few assets other than cash, inventory and the bauxite tenement.

Cash burn. Operating cash burn stabilised at about A$2.6–2.7m a year in FY2021–FY2022. At that rate the A$9.24m cash balance at 30 June 2022 implied about 3.4 years of runway. No figures after the Q2 FY2023 Appendix 4C (lodged 1 Feb 2023) have been located, so the current cash position is not publicly disclosed.

Dilution. Share count (consolidation-adjusted) rose about 4 times between June 2019 and June 2022. Equity was issued at A$0.035 (August 2019), then A$0.005 (FY2021) and about A$0.003 (October 2021), all pre-consolidation. Each raising was at a lower price than the last.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment and Revenue by Segment (%)

MetricFY2020FY2021FY2022

Cannabis segment revenue (AUD K)

1,805.01,488.0562.3

Mining segment revenue (AUD K)

000

Corporate segment revenue excl interest (AUD K)

00138.2

Cannabis share of operating revenue (%)

100100100

Cannabis segment revenue YoY growth (%)

275.5-17.6-62.2

Results by Segment and Segment Margins & Growth (%)

MetricFY2019FY2020FY2021FY2022

Cannabis segment loss before tax (AUD K)

-5,016.9-2,068.2-642.6-5,358.2

Mining segment loss before tax (AUD K)

-26.7-4.6-311.3-1.9

Corporate segment loss before tax (AUD K)

-4,190.8-5,978.0-3,816.7-3,719.2

Group loss before tax (AUD K)

-9,234.4-8,050.8-4,770.5-9,079.3

Cannabis segment margin on revenue (%)

-1,043.8-114.6-43.2-952.8

Segment Assets & Liabilities

MetricFY2019FY2020FY2021FY2022

Cannabis segment assets (AUD K)

3,389.56,497.85,800.01,584.2

Mining segment assets (AUD K)

2,260.72,471.92,288.92,287.8

Corporate segment assets (AUD K)

5,183.87,578.210,647.49,281.1

Group Entities

EntityCountryOwnership (%)Role

Cann Global Limited

Australia

Parent

Listed holding company

South Johnstone Bauxite Pty Ltd

Australia

100

Bauxite tenement holder

Volcan Queensland Bauxite Pty Ltd

Australia

100

Legacy mining

Medical Cannabis Limited

Australia

100

Seed bank, cannabis IP, research parent

Medical Cannabis Research Group Pty Ltd

Australia

100

Technion/MS research contracting entity

Vitahemp Pty Ltd

Australia

95

Vitahemp food brand

Vitaseeds Pty Ltd

Australia

100

Seeds

Vitacann Pty Ltd

Australia

100

Cannabis products

T12 Holdings Pty Ltd

Australia

100

Food division (Organic Markets Direct)

Hemp Hulling Co (QLD) Pty Ltd

Australia

55 (control lost Mar 2022, in voluntary administration)

Hemp seed hulling

Cann Global Asia Pty Ltd

Australia

55

Laos hemp project (abandoned)

Cann Global Thailand Pty Ltd

Australia

55

Thai cultivation/extraction services

Medical Cannabis (Cambodia) Co., Ltd

Cambodia

51

Dormant Asian vehicle

Canntab Therapeutics Australia

Australia

50 (equity-accounted JV)

Cannabinoid tablet distribution

Pharmocann Global Pty Ltd

Australia

50 (dissolved 7 Jul 2022)

Skincare JV

Income Statement and Per-Share Data

MetricFY2019FY2020FY2021FY2022

Revenue (AUD K)

480.61,781.71,488.0562.3

Cost of goods sold (AUD K)

562.21,311.91,162.3640.5

Gross profit (AUD K)

-81.6469.9325.7-78.2

Other income incl FX (AUD K)

030.6595.811.3

Total operating expenses (AUD K)

8,364.56,667.45,756.19,169.3

Operating income EBIT (AUD K)

-8,446.0-6,167.0-4,834.6-9,236.2

Depreciation and amortisation (AUD K)

62.179.1155.0232.5

EBITDA computed (AUD K)

-8,384.0-6,087.8-4,679.6-9,003.7

Finance income (AUD K)

123.3124.7163.6191.4

Finance costs (AUD K)

911.62,008.699.534.6

Pre-tax income (AUD K)

-9,234.4-8,050.8-4,770.5-9,079.3

Income tax (AUD K)

0000

Net income total (AUD K)

-9,234.4-8,050.8-4,770.5-9,079.3

Net income attributable to members (AUD K)

-6,434.9-8,012.1-4,621.4-8,218.0

Net loss attributable to non-controlling interests (AUD K)

-2,799.4-38.7-149.1-861.4

EPS basic as reported (AUD cents)

-0.57-0.26-0.10-3.68

EPS diluted as reported (AUD cents)

-0.57-0.26-0.10-3.68

Dividends per share (AUD cents)

0000

Margin Analysis (%)

MetricFY2019FY2020FY2021FY2022

Revenue growth YoY (%)

0270.7-16.5-62.2

Gross margin (%)

-17.026.421.9-13.9

Operating margin (%)

-1,757.2-346.1-324.9-1,642.5

EBITDA margin (%)

-1,744.3-341.7-314.5-1,601.2

Net margin total loss (%)

-1,921.3-451.9-320.6-1,614.6

Key Financials

MetricFY2019FY2020FY2021FY2022

Administrative and corporate (AUD K)

1,708.51,673.42,568.02,248.7

Directors fees CGB (AUD K)

714.0684.0699.7408.4

Research costs (AUD K)

407.92,130.3101.017.8

Legal expenses (AUD K)

713.5171.188.350.7

Share based payments (AUD K)

257.6773.9202.8418.5

Advertising and marketing (AUD K)

226.4207.3442.2292.2

Impairments and write-offs incl disposal loss (AUD K)

3,401.60889.34,873.7

Balance Sheet

MetricFY2019FY2020FY2021FY2022

Total assets (AUD K)

10,833.916,547.918,736.313,153.2

Cash and equivalents (AUD K)

5,183.87,417.110,573.19,240.1

Trade and other receivables (AUD K)

936.1709.6259.9190.4

Inventories (AUD K)

168.9489.5474.0510.0

Goodwill and intangibles (AUD K)

1,919.34,501.24,368.893.6

Exploration and evaluation asset (AUD K)

2,238.02,451.02,278.42,278.4

Short-term borrowings incl convertibles (AUD K)

6,405.04,290.777.50

Long-term borrowings (AUD K)

0000

Lease liabilities current (AUD K)

077.261.270.4

Lease liabilities non-current (AUD K)

061.20234.3

Plant funding liability (AUD K)

000254.8

Total debt incl leases excl plant funding (AUD K)

6,405.04,429.2138.7304.7

Net debt negative equals net cash (AUD K)

1,221.2-2,987.9-10,434.3-8,935.4

Total liabilities (AUD K)

7,946.96,789.82,392.43,660.8

Total equity (AUD K)

2,887.09,758.016,344.09,492.4

Accumulated losses (AUD K)

-29,858.4-37,870.5-42,491.9-50,709.9

Working capital (AUD K)

-1,554.72,042.28,977.66,672.9

Cash Flow

MetricFY2019FY2020FY2021FY2022

Operating cash flow (AUD K)

-3,871.1-4,776.3-2,743.0-2,642.8

Capex incl intangibles and exploration (AUD K)

399.9244.6181.1107.6

Free cash flow (AUD K)

-4,271.0-5,020.9-2,924.1-2,750.4

Equity issued for cash (AUD K)

06,618.66,654.61,692.0

Convertible and seed loan proceeds (AUD K)

3,127.12,833.200

Dividends paid (AUD K)

0000

Share buybacks (AUD K)

0000

Net change in cash (AUD K)

-1,225.52,193.93,156.0-1,333.0

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2019FY2020FY2021FY2022

ROE on average equity (%)

-127.9-127.3-36.6-70.3

ROA on closing assets (%)

-85.2-48.7-25.5-69.0

ROIC on invested capital (%)

-205.6-91.1-81.8-1,658.1

Current ratio (x)

0.801.304.752.95

Debt to equity incl leases (x)

2.220.450.010.03

Net debt to EBITDA (x)

-0.150.492.230.99

Interest coverage EBIT over finance costs (x)

-9.3-3.1-48.6-267.0

Asset turnover revenue over closing assets (x)

0.0440.1080.0790.043

Days sales outstanding trade receivables (days)

256.5113.758.093.5

Days inventory outstanding (days)

109.6136.2148.9290.6

Days payables outstanding trade payables (days)

769.1545.1552.41,242.4

Cash conversion cycle (days)

-403.0-295.2-345.5-858.3

Share Count (millions) and Per-Share Data

MetricFY2019FY2020FY2021FY2022

Ordinary shares on issue as reported (millions)

1,612.43,390.05,707.8258.9

Ordinary shares adjusted for 25 to 1 consolidation (millions)

64.5135.6228.3258.9

Weighted average shares as reported (millions)

1,611.73,143.44,909.3246.7

Net tangible assets per share as reported (AUD cents)

0.260.350.1692.578

Revenue by Region and Revenue by Region (%)

MetricFY2020FY2021FY2022

Australia revenue (AUD K)

1,050.21,123.3562.3

Rest of the World revenue (AUD K)

731.5364.70

Total revenue (AUD K)

1,781.71,488.0562.3

Australia share of revenue (%)

58.975.5100

Australia revenue growth YoY (%)

07.0-49.9

Rest of the World revenue growth YoY (%)

0-50.1-100

Revenue by Region

MetricFY2021FY2022

Hemp food products Australia (AUD K)

849.8379.8

Hemp food products Rest of World (AUD K)

80.20

Chia food products Australia (AUD K)

156.4125.2

Chia food products Rest of World (AUD K)

270.70

Other revenue Australia (AUD K)

117.257.4

Other revenue Rest of World (AUD K)

13.80

Revenue by Region (FY2020–FY2022)

MetricFY2020FY2021FY2022

Hemp seed (AUD K)

1,594.4305.8121.0

Hemp oil (AUD K)

26.2291.8108.9

Hemp protein (AUD K)

58.2129.494.2

Hemp capsules (AUD K)

10.5133.239.8

Hemp flour (AUD K)

23.310.910.1

Hemp by-products (AUD K)

1.757.25.8

Chia seed (AUD K)

0381.6105.7

Chia oil and capsules (AUD K)

029.814.6

Chia flour (AUD K)

015.74.9

Other incl services (AUD K)

67.4131.057.4

Per-Share Data and Returns & Leverage Ratios

MetricFY2020FY2021FY2022

Main capital raising price adjusted (AUD per share)

0.8750.1250.075

Main capital raising proceeds (AUD K)

5,950.07,827.51,800.0

Capital Markets

MeasureValueBasis

Market capitalisation

A$5.44m

258.87m shares × A$0.021

Net cash (30 Jun 2022)

A$8.94m

Cash A$9.24m less lease liabilities A$0.30m

Enterprise value

About −A$3.5m (negative)

Market cap − net cash

P/E

Not meaningful (loss-making)

FY2022 loss A$9.08m

EV/EBITDA

Not meaningful (negative EV and EBITDA)

—

EV/Sales

Not meaningful (negative EV)

—

P/B

0.57x

A$5.44m / A$9.49m equity

Price / net cash

0.61x

Market valued cash at a discount, reflecting expected burn and governance discount

Analyst Conclusions

Management guidance. None. The last forward-looking statements (April 2023 to February 2024) said that (i) a Thai asset acquisition was under detailed due diligence, (ii) outstanding financial reports would be finalised with a new auditor, HLB Mann Judd, and (iii) the company would then apply for re-quotation [ASX-ANN]. None of these steps has been publicly confirmed as completed.

Consensus growth expectations. None (no coverage).

Bull case (grounded in last disclosed data):

  1. Cash shell with real cash. At the last balance sheet (June 2022) the company held A$9.24m cash and no borrowings. Even after roughly two to three years of reduced burn, some cash may remain. A clean, debt-free unlisted shell with an established shareholder register can be a vehicle for a backdoor transaction.

  2. Optionality on residual assets. The A$2.28m bauxite exploration asset, the fully owned Fuss Pot brand, the Canntab JV interest (A$0.33m carrying value) and any surviving MS-strain rights give non-zero salvage value.

  3. Tax-loss shelter. Accumulated losses above A$50m (unrecognised deferred tax assets of A$7.1m tax effect at FY2020) could be valuable to an acquirer of a profitable business, subject to Australian continuity-of-ownership and business tests.

Bear case:

  1. No listing, no liquidity. Removal under LR 17.12 means investors cannot trade. Re-admission would need full re-compliance, a prospectus and audited accounts for missing years. The company's own 2018–2019 re-compliance took about a year and 15 supplementary prospectuses.

  2. Value erosion and reporting failure. Every operating venture shrank or failed: revenue −62%, goodwill fully written off, HHC in administration, partners terminated. The company also failed to pay listing fees and lodge accounts, so the last reliable cash figure is more than three years old.

  3. Governance and deregistration risk. Concentrated founder-family control and a history of related-party dealings, plus a 2026 ASIC strike-off scare, imply a high probability of eventual deregistration or minimal recovery for minority holders. deListed Australia assesses the shares as of little or no value.

Key catalysts and monitorables (next 12 months):

  • Lodgement of overdue FY2023–FY2026 financial statements with ASIC.

  • Any announcement on completion or termination of the Thai cannabis asset acquisition.

  • Any application for ASX re-admission or a reverse takeover.

  • ASIC registry status: a renewed strike-off or appointment of an external administrator would be decisive.

  • Status of the South Johnstone bauxite tenure and the Canntab JV commitments (A$0.90m outstanding at FY2022).

  • Any distribution or return of capital to shareholders from residual cash.

Concluding analyst verdict.

Cann Global Limited is a case study in failed micro-cap diversification during the 2016–2019 cannabis enthusiasm. In 2019 it converted a dormant bauxite explorer into a cannabis and health-food holding company, mostly by issuing shares: 1.15bn pre-consolidation shares valued at A$40.4m bought out minorities in Medical Cannabis Limited, and smaller share issues bought T12 and Hemp Hulling Co. Measured in revenue, the strategy peaked at A$1.78m in FY2020 and fell to A$0.56m with a negative gross margin by FY2022. Measured in shareholder value, the result was a 25:1 consolidation, accumulated losses of A$50.7m and a last traded price about 97.6% below the 2019 re-listing offer price on an adjusted basis.

The business had pockets of commercial validity: Costco listings, a chia omega-3 capsule, Canntab's tablets and a capital-light Thai services model. None reached a scale that could carry a corporate cost base running at roughly six to seven times revenue. Each venture depended on a partner (Epco, MedCan, Pharmocann, HHC), and each of those relationships failed or dissolved by mid-2022. Repeated, cheaper equity raisings and related-party arrangements further weakened minority investors' position.

The September 2022 suspension, nominally pending an acquisition, turned into an 18-month stand-off. A first transaction failed regulatory hurdles, listing fees went unpaid, financial reports were not lodged, and ASX removed the company in March 2024. The entity still exists, having survived an ASIC strike-off attempt in early 2026, and may hold some residual cash, a bauxite tenement and tax losses. However, there is no public financial information after early 2023, no trading venue and no stated plan.

Verdict: For institutional purposes, Cann Global should be treated as a non-investable, delisted shell with indeterminate and probably minimal residual equity value. Only a verified lodgement of audited accounts together with a credible re-compliance transaction would justify reassessment.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenurePrior roles / notes

David Austin

Independent Non-Executive Chair (from 30 Aug 2021)

Director since 15 Apr 2008

Long-standing NED; FY2021 directors' fees A$38.3k

Sholom Feldman

Managing Director & CEO

Director since 9 Nov 2007

Previously provided services through Australian Gemstone Mining Pty Ltd (AGMPL); took a 50% pay cut from Apr 2023 during the suspension

Jonathan Cohen

Independent Non-Executive Director

Since 2 Jul 2019

FY2021 directors' fees A$37.4k

Alexander J. Neuling

Company Secretary

Since about 15 May 2019

—

Executive Leadership Team

NameRoleTenureNotes

Pnina Feldman

Founder; Executive Chairperson

12 Apr 2007 – 30 Aug 2021

Controlled AGMPL. Granted 70m (pre-consolidation) shares for long service, subject to AGM approval in Nov 2021 [4E-FY21]

Marion Lesaffre

Chief Operating Officer

28 Aug 2020 – 24 Feb 2023

Almost 10 years with the company before appointment as COO [4E-FY20]

John Easterling

Non-Executive Director

2 Jul 2019 – 31 May 2022

Counterparty to the Olivia's Choice IP agreement (related-party, subject to shareholder approval) [4E-FY20]

Meyer Gutnick

Non-Executive Director

4 Mar 2014 – 2 Jul 2019

Lent A$115.0k to the company in FY2019, repaid FY2020 [4E-FY20]

Dr Robert Coenraads

Head Geologist

via AGMPL to FY2021, then employee

[4E-FY21]

Andrew Kavasilas

Technical Director, Medical Cannabis Ltd

—

Identified triploid cannabis trait (Tabulum Project); director loans A$694.0k at FY2019, repaid by FY2021

Eli Levy

Corporate head, food division

c.2019

[BNA]

Directors' Remuneration

MetricFY2019FY2020FY2021FY2022

KMP short-term benefits (AUD K)

714.0878.7920.2684.4

KMP share-based payments (AUD K)

0050.0312.0

KMP total compensation (AUD K)

714.0878.7970.2996.4

AGMPL related-party services paid (AUD K)

01,295.8660.00

AGMPL executive services component (AUD K)

0624.0624.00

Competitive Landscape

Competitors by Segment

SegmentCompetitorListing / status (as known)Relative positioning vs Cann Global

Hemp foods

Hemp Foods Australia

Acquired from Elixinol by Shanghai Shunho New Materials (SHE:002565), announced 3 Feb 2020

Established 1999; described as one of the Southern Hemisphere's largest hemp food wholesalers. Clear scale leader against CGB's food division

Hemp foods / CBD

Elixinol (ASX: EXL)

ASX-listed

Larger hemp food and CBD brand portfolio

Hemp foods / CBD

Ecofibre (ASX: EOF)

ASX-listed

Integrated hemp genetics, food and textiles; larger scale

Medicinal cannabis / hemp

ECS Botanics (ASX: ECS)

ASX-listed

Licensed cultivator/manufacturer; Owler lists it as a peer of Australian Organic alongside CGB

Medicinal cannabis

Cann Group (ASX: CAN)

ASX-listed

Licensed GMP cultivation; far larger asset base

Medicinal cannabis

Little Green Pharma (ASX: LGP)

ASX-listed

Licensed producer with own brands

Medicinal cannabis

Bod Australia (ASX: BDA)

ASX-listed

CBD products via TGA pathways

Medicinal cannabis

Zelira Therapeutics (ASX: ZLD)

ASX-listed

Clinical-trial-led cannabinoid medicines

Medicinal cannabis

AusCann Group (ASX: AC8, delisted Sep 2024)

Delisted for failing to pay listing fees

Parallel failure case: capsule formulations, similar end-state

Natural / organic foods

Australian Organic (private)

Private

Owler lists Cann Global among its top three competitors

Global cannabis

Canopy Growth (NASDAQ/TSX: CGC/WEED)

Listed

FY2022 (Mar-YE) net revenue C$520m; global benchmark showing sector-wide losses

Competitor Detail

MeasureCann Global (FY2022)

Revenue

A$0.56m [4E-FY22]

Revenue growth

−62.2%

Gross margin

−13.9%

Net margin

−1,614.6%

R&D intensity

3.2% of revenue

Licensed manufacturing

None owned

Recent Developments

Strict 18-month window (April 2025 – October 2026): * Public newsflow is minimal because the company has been delisted and is not reporting.

Company Snapshot

$0.4M

Revenue

2007

Founded

Sydney, Australia

Headquarters

SWOT Analysis

Strengths

  • Debt-free balance sheet after FY2021: borrowings fell from A$6.41m (FY2019) to A$0.08m (FY2021) and nil (FY2022) [4E-FY21], [4E-FY22].
  • Large cash buffer relative to the business at last report: A$9.24m cash against A$3.66m total liabilities at 30 Jun 2022 [4E-FY22].
  • Mass-retail listing achieved: Costco Australia orders for VitaHemp capsules (2019) and chia soft-gels (FY2021) [BNA], [4E-FY21].
  • Regulated medical product access: Canntab 12.5 mg/25 mg tablets cleared for SAS-B/AP in 2021 [4E-FY21].
  • Early Thai positioning: Cann Global Thailand reported a A$143.3k profit in its first operating period [4E-FY20].
  • Retained hard asset: South Johnstone bauxite exploration asset carried at A$2.28m [4E-FY22].

Weaknesses

  • Revenue fell to A$0.56m in FY2022 (−62.2% YoY) [4E-FY22].
  • Negative gross margin (−13.9%) in FY2022 [4E-FY22].
  • Corporate segment loss of A$3.72m against revenue of A$0.56m in FY2022 [4E-FY22].
  • Cumulative losses of A$50.7m at 30 Jun 2022 [4E-FY22].
  • All A$4.32m of acquisition goodwill (MCL, T12, HHC) written off in FY2022 [4E-FY22].
  • Governance concentration and related-party dependence: AGMPL fees of A$1.30m in FY2020; a A$1.2m director-related Volcan receivable fully impaired [4E-FY21].

Opportunities

  • A Thai cannabis asset acquisition with a route into Thailand, the EU and Australia (exclusivity secured October 2023) [ASX-ANN].
  • Monetising the South Johnstone bauxite tenement through sale or farm-out (A$2.28m book value) [4E-FY22].
  • Possible MS chemovar IP value if commercial rights survived the Pharmocann dissolution (status not disclosed) [4E-FY21].
  • Use of the clean, debt-free shell for a reverse takeover or re-compliance listing [ASX-ANN].
  • Fully owned Fuss Pot skincare brand after JV dissolution, keeping 100% of any revenue [4E-FY22].
  • Unrecognised tax losses (A$7.13m tax effect of revenue losses at FY2020) that could shelter a future profitable business, subject to continuity tests [4E-FY20].

Threats

  • Loss of ASX listing (1 Mar 2024) removes liquidity and the equity-funding route [DL].
  • Deregistration risk: ASIC strike-off was initiated in January 2026 [DL].
  • The proposed transaction already failed regulatory hurdles once (September 2023) [ASX-ANN].
  • Partner failure risk, already realised: Epco (COVID), MedCan (terminated), HHC (administration), Pharmocann (dissolved) [4E-FY21], [4E-FY22].
  • Thailand's cannabis policy volatility after liberalisation (general industry context; specific impact on CGB not disclosed).
  • Tenement lapse risk: the bauxite tenure renewal date (31 Oct 2022) has passed with no public update [4E-FY22].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
15 Jan 2026ASIC initiates strike-off action [DL]Signals possible non-lodgement of ASIC documents or inactivity
13 Feb 2026Status restored to "Registered" [DL]Directors or stakeholders took action to keep the entity alive (reason not disclosed)
Aug 2021FY2021 results: revenue A$1.49m (−16%), loss A$4.77m, cash A$10.57m [4E-FY21]Last year of relative stability
30 Aug 2021Founder Pnina Feldman retires; David Austin becomes Chair; AGMPL contract ends [4E-FY21]Governance reset
Aug 2021First Canntab 12.5 mg/25 mg CBD tablets cleared for SAS-B/AP [4E-FY21]First medical product in market
Oct 2021A$1.8m placement to sophisticated investors [HY22]Further dilution
Oct 2021Skincare range shown at CBD Expo, Paris [4E-FY21]European entry attempt
Nov 2021AGM; long-service share grant to the founder put to shareholders [4E-FY21]Related-party issuance
4 Feb 202225:1 share consolidation [4E-FY22]Capital structure clean-up
28 Feb 2022HY22: loss A$2.4m (+16.8% YoY); revenue reversal from accounting reclassification [HY22]Deteriorating trend
7 Mar 2022HY22 results webcast [HY22]Investor engagement
Mar 2022Hemp Hulling Co enters voluntary administration [4E-FY22]Loss of processing asset; A$1.88m loss
Apr 2022Q3 FY22 revenue reported down about 75% MarketScreener headlineRevenue collapse
May 2022CBD skincare range presented in Italy MarketScreener headlineMarketing only
31 May 2022John Easterling resigns as director [4E-FY22]Board shrinks to three
5 Jul 2022MedCan facilitation agreement terminated; fees disputed [4E-FY22]Loss of medical distribution partner
7 Jul 2022Pharmocann JV dissolved [4E-FY22]Skincare taken in-house; A$0.27m charge
1 Sep 2022FY2022 preliminary results: revenue A$0.56m (−62%), loss A$9.08m, goodwill fully written off [4E-FY22]Last full-year results
23 Sep 2022Voluntary suspension pending a proposed acquisition [ASX-ANN]Start of permanent suspension
3 Oct 2022FY2022 Annual Report lodged [ASX-ANN]Last annual report
13 Oct 2022Appendix 4G and Corporate Governance Statement [ASX-ANN]Last governance filing
21 Oct 2022Q1 FY23 Appendix 4C [ASX-ANN]Cash-flow update
30 Nov / 1 Dec 2022AGM held; results released [ASX-ANN]Last AGM on record
1 Feb 2023Q2 FY23 Appendix 4C [ASX-ANN]Last periodic report located
24 Feb 2023COO Marion Lesaffre steps down [DL]Management attrition
4 Apr 2023Brand streamlining, cost cuts, MD 50% pay reduction [ASX-ANN]Cash preservation
22 Aug 2023Failure to pay ASX annual listing fees for FY2024 [ASX-ANN]Red flag
15 Sep 2023Original material transaction failed regulatory hurdles [ASX-ANN]Deal failure
24 Oct 2023Thai asset exclusivity; 8.5m shares issued; delay in financial reports blamed on auditor change and staffing [ASX-ANN]New deal attempt; reporting default
1 Dec 2023Submissions made to ASX on the Thai transaction, conditional on lodging outstanding accounts [ASX-ANN]Re-quotation dependent on compliance
28 Feb 2024Auditor change to HLB Mann Judd in progress; FY2023 accounts outstanding [ASX-ANN]Final listed update
1 Mar 2024Removed from ASX Official List (LR 17.12) [DL]End of listing

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

8 charts
Income Statement: Revenue & Gross Profit: Revenue rose from AUD 0.5 Mn in FY2019 to AUD 0.6 Mn in FY2022.
Cann Global Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2019FY2020FY2021FY2022
Revenue0.51.81.50.6
Cost of goods sold0.61.31.20.6
Gross profit-0.10.50.3-0.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Cann Global Limited, Appendix 4E & Preliminary Financial Report FY2022 (unaudited), ASX, 1 Sep 2022 (asx.com.au)
  2. Cann Global Limited, 2021 Preliminary Financial Results & Appendix 4E, ASX, 31 Aug 2021 (asx.com.au)
  3. Cann Global Limited, 2020 Preliminary Financial Results & Appendix 4E, ASX, 31 Aug 2020 (asx.com.au)
  4. Cann Global Limited, Half-Year Report HY2022, 28 Feb 2022 (wcsecure.weblink.com.au)
  5. Cann Global Limited, Quarterly Report December 2018 (wcsecure.weblink.com.au)
  6. deListed Australia, Cann Global Limited (CGB) company record (delisted.com.au)
  7. InvestSMART, CGB delisted status and announcements (investsmart.com.au)
  8. Simply Wall St, Cann Global company profile (simplywall.st)
  9. Market Index, CGB page (marketindex.com.au)
  10. Stockopedia, CGB share price page (stockopedia.com)
  11. MarketScreener, Cann Global news and profile (marketscreener.com)
  12. Business News Australia, "Cann Global reports $3.5 million loss as it prepares to relist" (businessnewsaustralia.com)
  13. Business News Australia, "Rough start for Cann Global's return to the ASX" (direct.businessnewsaustralia.com)
  14. Business News Australia, "Cann Global high on Costco partnership" (direct.businessnewsaustralia.com)
  15. Stockhead, "Queensland Bauxite is back on the ASX, as pot stock Cann Global" (stockhead.com.au)
  16. CB Insights, Hemp Hulling company record (cbinsights.com)
  17. BDO, Shanghai Shunho acquisition of Hemp Foods Australia (bdo.com.au)
  18. Owler, Australian Organic competitors (owler.com)
  19. Wikipedia, AusCann (delisting context) (en.wikipedia.org)
  20. MJBizDaily, Canopy Growth FY2022 results (mjbizdaily.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.